1FW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro\* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich\* Lawrence J. Carroll\* George S. Bardmesser Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller\* LuAnne M. DeSantis John J. Figueroa Ann E. Summerfield Tiera S. Coston\* Aric W. Ledford\* Michael D. Specht Jessica L. Parezo Timothy A. Doyle\* Cynthia M. Bouchez Nicole D. Dretar\* Ted J. Ebersole

Registered Patent Agents -Karen R. Markowicz Nancy J. Leith Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Mary B. Tung Katina Y. Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukerjee Scott M. Woodhouse Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie \*Admitted only in Maryland \*Admitted only in Virginia \*Practice Limitled to Federal Agencies

May 5, 2004

WRITER'S DIRECT NUMBER: (202) 772-8851 INTERNET ADDRESS: RSCHWART@SKGF.COM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Art Unit 1624 -

Re:

U.S. Utility Patent Application

Application No. 09/836,548; Filed: April 18, 2001

For: Substituted 1,4-Thiazepine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof

Inventors:

Drewe et al.

Our Ref:

1735.0450001

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment and Reply Under 37 C.F.R. § 1.111; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents May 5, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Agent for Applicants Registration No. 50,211

RAS/law Enclosures

235052.1



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Drewe et al.

Appl. No.: 09/836,548

Filed: April 18, 2001

For: Substituted 1,4-Thiazepine and Analogs as Activators of Caspases

and Inducers of Apoptosis and the

**Use Thereof** 

Confirmation No.: 6789

Art Unit: 1624

Examiner: Coleman, B.

Atty. Docket: 1735.0450001/RWE/RAS

## Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated February 6, 2004, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.